DHA derivatives of fish oil as dietary supplements: A nutrition-based drug discovery approach for therapies to prevent metabolic cardiotoxicity

Yonggang Ma, Merry L. Lindsey, Ganesh V. Halade

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Introduction: During the early 1970s, Danish physicians Jorn Dyerberg and colleagues observed that Greenland Eskimos consuming fatty fishes exhibited low incidences of heart disease. Fish oil is now one of the most commonly consumed dietary supplements. In 2004, concentrated fish oil was approved as a drug by the FDA for the treatment of hyperlipidemia. Fish oil contains two major omega-3 fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). With advancements in lipid concentration and purification techniques, EPA- or DHA-enriched products are now commercially available, and the availability of these components in isolation allows their individual effects to be examined. Newly synthesized derivatives and endogenously discovered metabolites of DHA exhibit therapeutic utility for obesity, metabolic syndrome and cardiovascular disease. Areas covered: This review summarizes our current knowledge on the distinct effects of EPA and DHA to prevent metabolic syndrome and reduce cardiotoxicity risk. Since EPA is an integral component of fish oil, we will briefly review EPA effects, but our main theme will be to summarize effects of the DHA derivatives that are available today. We focus on using nutrition-based drug discovery to explore the potential of DHA derivatives for the treatment of obesity, metabolic syndrome and cardiovascular diseases. Expert opinion: The safety and efficacy evaluation of DHA derivatives will provide novel biomolecules for the drug discovery arsenal. Novel nutritional-based drug discoveries of DHA derivatives or metabolites may provide realistic and alternative strategies for the treatment of metabolic and cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)711-721
Number of pages11
JournalExpert Opinion on Drug Discovery
Volume7
Issue number8
DOIs
StatePublished - Aug 1 2012

Fingerprint

Docosahexaenoic Acids
Fish Oils
Drug Discovery
Dietary Supplements
Eicosapentaenoic Acid
Metabolic Diseases
Cardiovascular Diseases
Therapeutics
Obesity
Inuits
Greenland
Cardiotoxicity
Omega-3 Fatty Acids
Expert Testimony
Hyperlipidemias
Heart Diseases
Fishes
Physicians
Lipids
Safety

Keywords

  • Cardiovascular disease
  • Dietary supplement
  • Docosahexaenoic acid
  • Eicosapentaenoic acid
  • Fish oil
  • Metabolic syndrome
  • Obesity

ASJC Scopus subject areas

  • Drug Discovery

Cite this

DHA derivatives of fish oil as dietary supplements : A nutrition-based drug discovery approach for therapies to prevent metabolic cardiotoxicity. / Ma, Yonggang; Lindsey, Merry L.; Halade, Ganesh V.

In: Expert Opinion on Drug Discovery, Vol. 7, No. 8, 01.08.2012, p. 711-721.

Research output: Contribution to journalReview article

@article{d4d2f0722420425283cf15ab3d946560,
title = "DHA derivatives of fish oil as dietary supplements: A nutrition-based drug discovery approach for therapies to prevent metabolic cardiotoxicity",
abstract = "Introduction: During the early 1970s, Danish physicians Jorn Dyerberg and colleagues observed that Greenland Eskimos consuming fatty fishes exhibited low incidences of heart disease. Fish oil is now one of the most commonly consumed dietary supplements. In 2004, concentrated fish oil was approved as a drug by the FDA for the treatment of hyperlipidemia. Fish oil contains two major omega-3 fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). With advancements in lipid concentration and purification techniques, EPA- or DHA-enriched products are now commercially available, and the availability of these components in isolation allows their individual effects to be examined. Newly synthesized derivatives and endogenously discovered metabolites of DHA exhibit therapeutic utility for obesity, metabolic syndrome and cardiovascular disease. Areas covered: This review summarizes our current knowledge on the distinct effects of EPA and DHA to prevent metabolic syndrome and reduce cardiotoxicity risk. Since EPA is an integral component of fish oil, we will briefly review EPA effects, but our main theme will be to summarize effects of the DHA derivatives that are available today. We focus on using nutrition-based drug discovery to explore the potential of DHA derivatives for the treatment of obesity, metabolic syndrome and cardiovascular diseases. Expert opinion: The safety and efficacy evaluation of DHA derivatives will provide novel biomolecules for the drug discovery arsenal. Novel nutritional-based drug discoveries of DHA derivatives or metabolites may provide realistic and alternative strategies for the treatment of metabolic and cardiovascular disease.",
keywords = "Cardiovascular disease, Dietary supplement, Docosahexaenoic acid, Eicosapentaenoic acid, Fish oil, Metabolic syndrome, Obesity",
author = "Yonggang Ma and Lindsey, {Merry L.} and Halade, {Ganesh V.}",
year = "2012",
month = "8",
day = "1",
doi = "10.1517/17460441.2012.694862",
language = "English (US)",
volume = "7",
pages = "711--721",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - DHA derivatives of fish oil as dietary supplements

T2 - A nutrition-based drug discovery approach for therapies to prevent metabolic cardiotoxicity

AU - Ma, Yonggang

AU - Lindsey, Merry L.

AU - Halade, Ganesh V.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Introduction: During the early 1970s, Danish physicians Jorn Dyerberg and colleagues observed that Greenland Eskimos consuming fatty fishes exhibited low incidences of heart disease. Fish oil is now one of the most commonly consumed dietary supplements. In 2004, concentrated fish oil was approved as a drug by the FDA for the treatment of hyperlipidemia. Fish oil contains two major omega-3 fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). With advancements in lipid concentration and purification techniques, EPA- or DHA-enriched products are now commercially available, and the availability of these components in isolation allows their individual effects to be examined. Newly synthesized derivatives and endogenously discovered metabolites of DHA exhibit therapeutic utility for obesity, metabolic syndrome and cardiovascular disease. Areas covered: This review summarizes our current knowledge on the distinct effects of EPA and DHA to prevent metabolic syndrome and reduce cardiotoxicity risk. Since EPA is an integral component of fish oil, we will briefly review EPA effects, but our main theme will be to summarize effects of the DHA derivatives that are available today. We focus on using nutrition-based drug discovery to explore the potential of DHA derivatives for the treatment of obesity, metabolic syndrome and cardiovascular diseases. Expert opinion: The safety and efficacy evaluation of DHA derivatives will provide novel biomolecules for the drug discovery arsenal. Novel nutritional-based drug discoveries of DHA derivatives or metabolites may provide realistic and alternative strategies for the treatment of metabolic and cardiovascular disease.

AB - Introduction: During the early 1970s, Danish physicians Jorn Dyerberg and colleagues observed that Greenland Eskimos consuming fatty fishes exhibited low incidences of heart disease. Fish oil is now one of the most commonly consumed dietary supplements. In 2004, concentrated fish oil was approved as a drug by the FDA for the treatment of hyperlipidemia. Fish oil contains two major omega-3 fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). With advancements in lipid concentration and purification techniques, EPA- or DHA-enriched products are now commercially available, and the availability of these components in isolation allows their individual effects to be examined. Newly synthesized derivatives and endogenously discovered metabolites of DHA exhibit therapeutic utility for obesity, metabolic syndrome and cardiovascular disease. Areas covered: This review summarizes our current knowledge on the distinct effects of EPA and DHA to prevent metabolic syndrome and reduce cardiotoxicity risk. Since EPA is an integral component of fish oil, we will briefly review EPA effects, but our main theme will be to summarize effects of the DHA derivatives that are available today. We focus on using nutrition-based drug discovery to explore the potential of DHA derivatives for the treatment of obesity, metabolic syndrome and cardiovascular diseases. Expert opinion: The safety and efficacy evaluation of DHA derivatives will provide novel biomolecules for the drug discovery arsenal. Novel nutritional-based drug discoveries of DHA derivatives or metabolites may provide realistic and alternative strategies for the treatment of metabolic and cardiovascular disease.

KW - Cardiovascular disease

KW - Dietary supplement

KW - Docosahexaenoic acid

KW - Eicosapentaenoic acid

KW - Fish oil

KW - Metabolic syndrome

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=84864369256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864369256&partnerID=8YFLogxK

U2 - 10.1517/17460441.2012.694862

DO - 10.1517/17460441.2012.694862

M3 - Review article

C2 - 22724444

AN - SCOPUS:84864369256

VL - 7

SP - 711

EP - 721

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 8

ER -